https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Wed 11 Apr 2018 14:11:46 AEST ]]> Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19871 Wed 11 Apr 2018 14:09:42 AEST ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS-I) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29519 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Wed 11 Apr 2018 12:50:17 AEST ]]> Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14178 Wed 11 Apr 2018 11:03:59 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> Preventive therapy for breast cancer: a consensus statement https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17172 Sat 24 Mar 2018 08:06:31 AEDT ]]> Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17734 Sat 24 Mar 2018 07:57:38 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]> Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23224 Sat 24 Mar 2018 07:10:39 AEDT ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]>